Q-omics provides the consensus-scored TMEM241 profile across patient tissues and cancer cell-line models. TMEM241 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, TMEM241 is differentially expressed in 17, with the highest sampling consensus in COAD. Additionally, TMEM241 RNA expression shows 20,447 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and COAD as cancer lineages where TMEM241 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM241 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM241 survival associations across molecular data types. TMEM241 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (5) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM241 RNA expression–survival associations across cancer types. High TMEM241 expression shows unfavorable associations in ACC, LIHC, BLCA and COAD, but favorable associations in LUAD and KIRC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for TMEM241 RNA expression.
This table summarizes TMEM241 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 17. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for TMEM241. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM241 shows higher tumor expression in COAD, BLCA, LUAD, KIRC, BRCA and STAD. The COAD box plot shows higher TMEM241 RNA expression in tumor versus normal tissue (log2 FC = +0.899, t-test p < 0.001).
This table shows molecular features associated with TMEM241 in patient tissues and cancer cell lines. In patient samples, TMEM241 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM241 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Lymphoma.
